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Abstract
Hepatitis C virus (HCV) is a global problem. To better understand HCV infection researchers employ in vitro HCV cell-culture
(HCVcc) systems that use Huh-7 derived hepatoma cells that are particularly permissive to HCV infection. A variety of hyper-
permissive cells have been subcloned for this purpose. In addition, subclones of Huh-7 which have evolved resistance to
HCV are available. However, the mechanisms of susceptibility or resistance to infection among these cells have not been
fully determined. In order to elucidate mechanisms by which hepatoma cells are susceptible or resistant to HCV infection we
performed genome-wide expression analyses of six Huh-7 derived cell cultures that have different levels of permissiveness
to infection. A great number of genes, representing a wide spectrum of functions are differentially expressed between cells.
To focus our investigation, we identify host proteins from HCV replicase complexes, perform gene expression analysis of
three HCV infected cells and conduct a detailed analysis of differentially expressed host factors by integrating a variety of
data sources. Our results demonstrate that changes relating to susceptibility to HCV infection in hepatoma cells are linked
to the innate immune response, secreted signal peptides and host factors that have a role in virus entry and replication. This
work identifies both known and novel host factors that may influence HCV infection. Our findings build upon current
knowledge of the complex interplay between HCV and the host cell, which could aid development of new antiviral
strategies.
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Introduction
Hepatitis C virus (HCV) is prevalent in approximately 3% of
the human population, though some countries, e.g., Eygpt, have a
much greater prevalence [1]. The acute phase of infection is often
asymptomatic whereas chronic infection is a major cause of liver
cirrhosis, hepatocellular carcinoma and liver transplantation.
Unfortunately there is no HCV vaccine. A high level of virion
production, combined with the error-prone HCV RNA polymer-
ase, causes frequent mutation of the viral genome resulting in
production of immune escape mutants. Treatment of chronic
HCV infection is currently based on interferon-a that evokes a
general antiviral response and ribavirin, a nucleoside analogue. In
combination, these antiviral agents do not reliably eradicate HCV
in infected patients [2] and, in addition, treatment is often
interrupted due to the side effects that these drugs cause [3].
Therefore, development of improved anti-HCV drugs would be of
great benefit.
Drugs that bind specific host proteins essential to the virus life
cycle pose an attractive approach in viral disease therapy, as these
targets have less potential for mutation and associated emergence
of resistance than viral protein targets. Thus, anti-HCV drugs that
bind specific host proteins are currently in development. For
example alisporivir, a Cyclophilin A inhibitor, has recently entered
phase II trials [4]. Cyclophilin A is essential for efficient HCV
replication, probably due to direct physical interaction with NS5A
and mediation of the viral polymerase [5,6]. Also, inhibitors to
microRNA mir-122, a molecule that regulates production of
infectious virus particles, are also being investigated [7,8]. By
developing a greater understanding of the complex interplay
between HCV and host cells, novel drug targets might be
identified.
Significant advances in in vitro model systems to study HCV-host
interactions have been made in the recent past [9]. Model systems
greatly accelerated HCV research and led to production of a
variety of genome-scale data sets including a host-virus interaction
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network [10], infection-induced changes in gene expression
[11,12] and host factors required for viral replication [5]. In
addition to large data sets, numerous small-scale studies that use in
vitro model systems have captured important details of key viral
processes, such as virus cell entry [13]. However, we are still some
considerable way from fully understanding the HCV life cycle and
the role for each implicated host factor.
The initial breakthrough in HCV model systems allowed study
of genomic viral RNA replication in vitro using replicons and
permissive Huh-7 hepatoma cell lines [14,15]. More recent HCV
cell-culture (HCVcc) systems have permitted study of the entire
virus life cycle and rapid cell-to-cell transmission, using a specific
combination of the JFH-1 HCV strain and a particularly
permissive hepatoma cell line (Huh-7.5.1) [9,16]. The Huh-7.5.1
cells have a deactivating mutation in retinoic acid-inducible gene I
(RIG-I), a protein that would normally bind to HCV RNA and
initiate an interferon based antiviral response in the cell [17,18].
Also, further subcloning of Huh-7.5.1 has led to the production of
a more permissive cell (designated Huh-7.5.1c2 [19]), though the
underlying mechanism of increased permissiveness in this subclone
is not understood.
In addition to HCV susceptible cells, infection resistant Huh-7
derived cells have also been produced. One HCVcc study by
Zhong et al. [20], a prerequisite to this study, detected coevolution
of JFH-1 HCV virus and Huh-7 and Huh-7.5.1 derived host cells.
In particular, evolution of an increasingly aggressive virus was
associated with emergence of several resistant cells. Follow-up
analysis revealed that reduced cell surface expression of the CD81
viral coreceptor [21,22] was partly responsible for resistance in a
subset of these cells and that additional defects must be present
that perturb the viral life-cycle. Therefore, mechanisms of both
HCV resistance and susceptibility for Huh-7 derived cells are yet
to be determined. This knowledge will be valuable for under-
standing specific host-cell dependencies in the viral life cycle and
developing novel antiviral strategies.
In order to elucidate mechanisms by which hepatoma cells are
susceptible or resistant to HCV infection we performed genome
wide expression analysis of six Huh-7 derived cell cultures that
have different levels of permissiveness to infection (figure 1A). To
focus our investigation, we identified host proteins from HCV
replicase complexes that were present in small vesicles located in
the membranous web – a specific membrane alteration that is the
site of HCV replication [23] – and also performed gene expression
analysis of three permissive HCV infected cells. We found that a
great number of genes, representing a wide spectrum of functions,
including factors known to be involved in viral entry were
differentially expressed between cells with different permissiveness
to infection. Following this we conducted an in-depth analysis of
differentially expressed host factors by integrating multiple data
sources. Using this approach, we demonstrate that changes
relating to susceptibility to HCV infection can be specifically
linked to the innate immune response, secreted signal peptides,
known host factors that influence virus entry and replication and
putative, novel HCV infection-related host factors. In addition,
our study also helps to characterise Huh-7 derived cells which may
aid interpretation of results from subsequent studies that use
HCVcc.
Results and Discussion
HCV infection causes significant changes to gene
expression
Expression analysis of three hepatoma cell cultures – Huh-7,
Huh-7.5.1 and Huh-7.5.1c2 – that are susceptible to infection was
Figure 1. Tree of hepatoma cell cultures. Cell cultures are joined
by arrows, going from the parent to the descendent, that indicate a
subcloning event (or in the case of Huh-7 to Huh-7.5.1 a series of
subcloning events). (A) The relative susceptibility of these cells to HCV
infection where ‘‘+’’ represents susceptibility and ‘‘-’’ represents
resistance and more symbols represent greater susceptibility or
resistance. (B) Differential expressed genes between subclones.
Differentially expressed genes were assigned to this tree either directly
from expression comparison between cells or indirectly using a
parsimony method. On each arrow, the first number indicates the total
number of differentially expressed genes that have been attributed to
the subcloning event. Below in brackets are the number of these genes
that are (i) downregulated or (ii) upregulated following subclononing.
doi:10.1371/journal.pone.0025584.g001
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performed. By comparing infected and uninfected cells we
identified genes that are differentially expressed (false discovery
rate corrected p-value ,0.01), in all cell lines: 1743 genes in Huh-
7 (1525 upregulated, 218 downregulated); 7025 in Huh-7.5.1
(3503 upregulated, 3522 downregulated); and 3891 in Huh-
7.5.1c2 (1485 upregulated, 2406 downregulated), (supplementary
table S1). This represents 7475 distinct genes, 54% of all genes
analysed. 3835 of these genes (51%) were differentially expressed
in more than one cell and 1181 (16%) were differentially expressed
with the same response to infection (up- or downregulation) in all
three comparisons. A hierarchical clustering plot (figure 2) shows a
clear pattern of gene expression that corresponds to infection by
HCV. Intersections between these gene sets are shown in figure 3.
Previously, Woodhouse et al. [24] performed whole genome
expression analysis of Huh-7.5 cells infected with JFH1 HCV,
harvested at the peak of infection and identified 1351 differentially
expressed genes. Though we identify more differentially expressed
genes, our results overlap significantly with those of Woodhouse
et al. for all three cells (p,0.01, Fisher’s exact tests) and the
response to infection of genes identified in both studies is well
conserved at 90-99% for each cell line.
By performing functional annotation clustering on the subset of
1181 genes found to be differentially expressed with the same
response to infection over all infected versus control cell
comparisons (figure 3, section G), we identifiy a core set of host
cellular functions that are affected by HCV infection (supplemen-
tary table S2). Interestingly, the two most enriched clusters comprise
genes involved in transcription. Zinc-finger domain containing
proteins are highly over-represented in this set (249 genes are
annotated with the SwissProt keyword ‘‘zinc-finger’’ [25]) (false-
discovery-rate corrected p-value of 8.6610229). The change in
expression of such a large number of zinc-finger domain encoding
genes remains unexplained, particularly as many of these factors are
not known to be associated with viral infection. However, of these
249 proteins, 143 are also annotated with the SwissProt keyword
"transcription regulation". Given the scale of change in gene
expression between infected and uninfected cells, extensive change
in the expression of transcriptional regulators is fitting.
In addition, other cellular processes including microtubule
organisation, ubiquitin and ubiquitin-like (ubl) conjugation
pathway and DNA repair (particularly DEAD and DEAH box
helicases) are enriched. HCV requires a functional microtubule
network for entry into Huh-7.5 cells and early post-entry steps of
infection through interaction with tubulin proteins [26]. We
identify 11 tubulin isoforms that are either up- or down-regulated
during HCV infection, indicating that HCV infection may exert
control over the microtubule network at the level of transcription.
DEAD box helicases, RIG-I and IFIH1, are interferon
stimulated genes (ISGs) that act to detect RNA viruses and initiate
further interferon production [18]. Another DEAD box helicase,
DDX3X, encodes a factor that is required for successful HCV
replication [5,27,28]. However, DDX3X can also cause immune
activation [29] and the role for this protein in HCV infection is
unclear. RIG-I is transcriptionally upregulated in Huh-7 and Huh-
7.5.1 cells but not Huh-7.5.1c2 following infection, and IFIH1 is
transcriptionally upregulated in Huh-7.5.1 cells but not Huh-7 or
Huh-7.5.1c2 following infection. These results indicate a potential
weakness in the innate immunity of Huh-7.5.1c2 at the level of
gene expression.
Virally triggered RIG-I mediated antiviral signaling evokes the
production of type I interferon [30]. However, in our results we do
not observe increase in transcription of type I interferon in either
Huh-7 cells that have functional RIG-I or Huh-7.5 derived cells
whose RIG-I gene has a known deactivating mutation [17]. This
Figure 2. Hierarchical clustering plot displaying differentially
expressed genes from infected and control cells. Genes are
represented by horizontal bands and cells by columns. Infected cells are
denoted with an asterisk (*). Bands are coloured blue if the gene is
downregulated and yellow if it is upregulated compared with the mean
expression level for that gene. Greater colour intensity signifies greater
fold change. Infected cells cluster with one another and gene clustering
shows a clear pattern that corresponds to HCV infection-induced
regulation of gene expression.
doi:10.1371/journal.pone.0025584.g002
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result suggests that HCV successfully attenuates interferon
production. The virus can achieve interferon attenuation through
several mechanisms including NS3/NS4A protease activity that
disrupts both RIG-I and toll-receptor signaling [30]. The
regulation of ISGs following infection of hepatoma cells was
investigated. A list of ISGs was obtained from the ISG database
[31] and a total of 455 genes were present in the ISG data and also
present in our microarray gene set. We find that 62, 198 and 160
ISGs are differentially expressed in Huh-7, Huh-7.5.1 and Huh-
7.5.1c2 cells, respectively, following HCV infection. However,
these values do not represent statistically significant enrichment of
ISGs, consistent with our observation regarding lack of significant
transcriptional upregulation of interferon.
Ubiquitin conjugation has been identified as an important
cellular function for both viral and bacterial pathogens [32].
Firstly, deubiquitylating enzymes (DUBs), such as ubiquitin
specific peptidases (USPs) can modulate host cell innate immunity
[32]. Ubiquitin-like protein ISG15 is an ISG that is expressed
following infection and target proteins become ‘‘ISGylated’’
following conjugation of ISG15. Ubiquitin specific peptidase
USP18 is involved in deISGylation to attenuate innate immunity
[32,33]. Another USP, USP7, is targeted by viral proteins. USP7
interacts with both the herpes-simplex virus protein ICP0 and
Epstein-Barr nuclear antigen I and may have a role in regulation
viral replication [34,35]. We find that 27 USPs (though not
including those specific USPs mentioned) are differentially
expressed in one or more infected versus uninfected comparisons
and, given all comparisons, there are 59 instances of differential
expression of these genes from which 56 instances identify USP as
transcriptionally upregulated in the infected cell.
Another DUB that has a role in pathogenic infection is CYLD.
CYLD expression is induced in cells infected with Haemophilus
influenza and the absence of this gene confers hypersensitivity to
this bacterial pathogen [32]. In our results, CYLD is also
upregulated in all HCV infected cells. Therefore it seems likely
that DUB downregulation is a significant marker for HCV
infection in these cells and this could be related to activation of an
antiviral response, though presumably not via the RIG-I pathway
or interferon upregulation. Interestingly, HCV NS5A has been
shown by a yeast-two-hybrid assay to interact with USP19 [10], a
DUB known to positively regulate cell proliferation [36]. The
functional role of this protein interaction is not known and further
experimental validation and investigation could provide valuable
insight in to HCV infection.
Functional annotation clustering was repeated on gene sets from
sections A, B, C and F of the Venn diagram in figure 3 (see
supplementary table S2). The intersection of genes regulated with
the same response from Huh-7.5.1 and Huh-7.5.1c2 but not Huh-
7 infection studies (figure 3, section F, 1020 genes) is enriched for
functions that can be directly attributed to heightened HCV
infection, e.g., transforming growth factor b signaling [37] and a
generally heightened metabolic state, e.g., positive regulators of
transcription. Interestingly, one function whose enrichment is
found in section C of the Venn diagram (corresponding to the set
of genes differentially expressed following infection of Huh-7.5.1c2
cells), but not sections A or B (corresponding to infection of both
Huh-7 and Huh-7.5.1), is apoptosis. More specifically, the most
overrepresented annotation terms in this cluster refer to the
negative regulation of cell death and these genes are predomi-
nantly upregulated in infected Huh-7.5.1c2. Specifically, there are
21 genes annotated with the GO term negative regulation of cell death
and 16 of these are transcriptionally upregulated in infected Huh-
7.5.1c2 cells. For example, NFKB and BCL2 genes are established
as anti-apoptotic proliferative factors in human cancers and both
are upregulated in infected Huh-7.5.1c2. Apoptosis is an
important defense mechanism against infection that is initiated
by the innate immune response [38] and this result indicates that
Huh-7.5.1c2 could be a more permissive host for HCV than either
Huh-7 or Huh-7.5.1 by being less prone to apoptosis.
Subclones of Huh-7 derived cells have significantly
altered gene expression
We performed gene expression analysis on six cell cultures that
display a range of susceptibilities to HCV infection: HCV
susceptible Huh-7, Huh-7.5.1 and Huh-7.5.1c2 and HCV
resistant subclones of Huh-7.5.1, R1.09, R1.10 and R2.1.
Differentially expressed genes were detected in all comparisons
with a false discovery rate corrected p-value of ,0.01 and
minimum fold-change of 1.5. To identify differences in gene
expression between these cells, ‘parent-child’ cell comparisons
were made (see table 1 for a summary and supplementary S1 for
full details).
The pattern of gene regulation highlighted in heatmaps (figure 4)
correlates with the subcloning of these cells, where the ‘child’
subclone retains a significant proportion of the gene expression
profile of the ‘parent’. For example, many of the same genes are
found to be differentially expressed with the same direction of
regulation in the comparisons: (i) Huh-7.5.1 versus Huh-7 and
Huh-7.5.1c2 versus Huh-7 (1479 genes in common) and (ii) R1.09
versus Huh-7.5.1 and R1.10 versus Huh-7.5.1 (1424 genes in
common). Therefore, we represent cells and differential expression
on a hierarchical tree structure figure 1. This shows all six cells and
the total numbers of differentially expressed genes, both
upregulated and downregulated. A full list of differentially
Figure 3. Venn diagram showing the overlap in genes
differentially expressed due to HCV infection among suscep-
tible cells. The absolute numbers of significantly differentially
expressed genes are given for Huh-7, Huh-7.5.1 and Huh-7.5.1c2 cells.
The numbers in brackets refer to those genes that share the same
direction of regulation (up- or downregulated) following infection,
across multiple comparisons.
doi:10.1371/journal.pone.0025584.g003
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expressed genes for each branch is given in supplementary table
S3. A total of 7503 genes are differentially expressed following
subcloning events. This represents a substantial proportion of both
all genes on the microarray (42%) and the subset of those that are
expressed in these cells (54%). This indicates that multiple changes
in expression could contribute to the susceptibility to infection
found among the hepatoma cells.
Genes that are differentially expressed following subcloning
events were found to be enriched for specific biological
annotations using functional annotation clustering. A brief
summary of the most significant annotation clusters identified
among each set of genes is given in table 2 and a full list of results is
given in supplementary table S4. From table 2 it is clear that some
areas of biological annotation are significantly enriched among
more than one set of genes. For example, an annotation cluster
corresponding to secreted glycoproteins and signal peptides
appears in five out of the six sets and three out of five also include
an annotation cluster that corresponds to proteins of the acute
inflammatory response.
To assess (i) overlap in biological function between each set of
differentially expressed genes, (ii) overlap in biological function
these gene sets may have with other genes that relate to HCV
infection and (iii) to identify potential functions that contribute to
susceptibility to HCV infection, we created a functional clustering
network using all significant annotation clusters described in
supplementary table S4. This functional clustering network
comprises 36 subnetworks, shown in supplementary figure S1.
These subnetworks correspond to areas of shared, enriched
biological function between the gene sets. Figure 5 shows 12 of
these subnetworks that include at least three nodes, at least one
node corresponding to an enriched function from a subcloning
event and at least one node corresponding to an enriched function
from an additional data set linked directly to HCV infection.
These visualisations highlight the possibility that changes in
expression of genes of some of these particular functions may
contribute to susceptibility to HCV infection in more than one
subcloning event. For example, figure 5B shows that genes
encoding protein products that interact with proteins of HCV and
also genes that are differentially expressed between several
independent subcloning events (corresponding to both increase
and decrease in susceptibility to HCV infection), are all enriched
for extracellular and secreted disulphide-bond containing proteins
and signal peptides.
The subcloning of hepatoma cells has caused extensive changes
to transcriptional activity, both in terms of the absolute number of
differentially regulated genes and of biological functions affected.
In the case of Huh-7.5 cells, RIG-I mutation is known to increase
susceptibility to HCV infection and complementing these cells
with wild-type RIG-I induces greater resistance [17]. However,
differential expression of over 2000 genes from a variety of
functions between Huh-7 and Huh-7.5.1 is not necessarily due to a
single mutation of RIG-I, indeed this seems unlikely. Therefore, it
is impossible to say whether Huh-7.5.1 derived cells are more
susceptible than Huh-7 due to RIG-I alone, as change in
regulation of other genes may also play a role. Huh-7.5 derived
cells are commonly used for HCVcc but the extent to which
subcloning-induced cellular alteration distances these cells from
hepatocytes that are being modeled warrants greater consideration
given the scale of change we report.
A previous study by Inoue et al. [39] made comparison of two
Huh-7 subclones that had varying HCV replication efficiency.
Figure 4. Hierarchical clustering plots showing the expression
levels of differentially expressed genes between hepatoma
cells. Genes are represented by horizontal bands and cells by columns.
Bands are coloured blue if the gene is downregulated and yellow if they
are upregulated relative to their expression in Huh-7.5.1. Greater colour
intensity relates to a greater fold change. Black bands represent genes
whose expression is a similar level to Huh-7.5.1. (A) Comparison of gene
expression levels between susceptible cells. Here, the Huh-7.5.1c2 cell
line is clearly more similar in gene expression to Huh-7.5.1 than Huh-7.
(B) Comparison of gene expression levels between resistant cells and
Huh-7.5.1. The R2.1 cell line is more divergent from Huh-7.5.1 than
either R.109 or R1.10 in terms of gene expression. R1.09 and R1.10 show
similar patterns of gene expression.
doi:10.1371/journal.pone.0025584.g004
Table 1. The number of differentially expressed (DE) genes identified in pairwise comparison between cells.
Original cell Subclone cell Total DE genes Downregulated in subclone Upregulated in subclone
Huh-7 Huh-7.5.1 2036 1148 888
Huh-7.5.1 Huh-7.5.1c2 187 119 68
Huh-7.5.1 R1.09 2830 1534 1296
Huh-7.5.1 R1.10 1714 771 943
Huh-7.5.1 R2.1 5682 2470 3212
The genes were found to be differentially expressed with a false discovery rate corrected p-value of ,0.01.
doi:10.1371/journal.pone.0025584.t001
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Inoue et al. identify 17 genes that have an increased level of
expression and 19 genes that have a decreased level of expression
in the more efficient of the cells. Though the present study and
that of Inoue et al. have a shared aim, there is very little
concurrence of results. This could be because Inoue et al. observed
a different mechanism causing change in susceptibility to infection
but it could also be due to the relatively small size of their result
set. Regardless, our study has greater power as six Huh-7 derived
subclones rather than two were analysed and expression of
approximately 17 thousand genes, as opposed to approximately
8500 were assessed.
Host factors linked to HCV are differentially expressed in
subclones of Huh-7
HCV dependency factors. The 7503 genes differentially
expressed following subcloning events are enriched for genes
shown by siRNA gene knockdown to be necessary for HCV
replication [5,28,40–42], termed HCV dependency factors
(HDFs). A total of 292 genes that are expressed among the six
cells are among HDFs and 176 of these genes are differentially
expressed (P= 0.050, Fisher’s exact test). This result indicates
that differences in expression are likely to impact susceptibility
of the cells to infection.
Table 2. Functional enrichment among significantly differentially expressed genes between original cells and subclones.
Original cell Subclone cell No. clusters No. genes Top 5 clusters
ES.2 ES.2 ES No. genes Annotations
Huh-7 Huh-7.5.1 15 866 5.81 565 Extracellular and secreted; signal peptide;
glycoprotein; disulfide bond.
4.93 119 Response to hormone stimulus and organic
substance.
3.92 47 Response to steroid hormone and glucocorticoid
stimulus.
3.52 48 Response to extracellular stimulus, nutrients,
retinoic acid and vitamin A.
3.37 37 Complement and coagulation cascades; acute
inflammatory and defense response.
Huh-7.5.1 Huh-7.5.1c2 2 108 7.09 83 Glycoprotein; signal peptide; secreted; disulfide
bond.
4.93 74 Response to hormone stimulus and organic
substance.
10.55 416 Extracellular and secreted; signal peptide;
glycoprotein; disulfide bond.
Huh-7.5.1 R1.1 18 704 5.03 88 Response to wounding; acute inflammatory and
defense response.
4.42 113 Mitosis; organelle fission; cell-cycle; M-phase.
4.23 54 Enzyme inhibitor; endopeptidase and protease
inhibitor; SERPIN family; reactive bond.
3.60 50 Proteinaceous extracellular matrix; basement
membrane.
11.32 108 DNA replication and DNA metabolic process.
R1.1 R1.09 13 582 7.07 151 Mitosis; organelle fission; cell division; chromosome
segregation;cell-cycle; M-phase.
6.41 96 Chromosomal part; centromeric region; chromatin.
5.46 140 DNA repair; response to DNA damage; stress
response.
4.85 45 Condensed chromosome; kinetochore; centromeric
region .
R1.1 R1.10 2 108 4.12 55 Extracellular space.
4.09 108 Secreted; signal peptide; glycoprotein; disulfide
bond.
6.34 165 Sequence-specific DNA binding; Homeobox DNA
binding domain.
Huh-7.5.1 R2 25 1325 4.97 95 Embryonic morphogenesis; appendage
development.
4.93 40 Acute inflammatory response; acute phase.
4.74 153 Acute inflammatory, wounding and defense response.
4.59 73 Extracellular and secreted; signal peptide;
glycoprotein; disulfide bond.
Shown are the number of functional annotation clusters that achieve an enrichment score (ES) of .2 and the number of differentially expressed genes that these
clusters include. The right-most three columns give details of the top scoring annotation clusters (a maximum of 5 are shown).
doi:10.1371/journal.pone.0025584.t002
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Figure 5. Functional annotation cluster networks from differentially expressed genes and other HCV-related data sources. These
networks highlight areas of shared enriched function between gene sets that we identify as differentially expressed between hepatoma cells and also
gene sets that relate to HCV infection. Nodes represent annotation clusters from the data source denoted by the node colour. Edges represent shared
annotation terms between clusters. Only nodes that share at least 1/4 of annotating terms are connected by an edge. Node diameter is proportional
to the level of enrichment of the biological function in the gene set. Edge width is proportional to the proportion of annotating terms shared
between two clusters. Subnetworks A–D are those with .6 nodes, subnetworks shown in E have between 3 and 6 nodes. Annotation clusters from
two PPI data sources are shown: PPI (1) from reference [10] and PPI (2) from reference [69].
doi:10.1371/journal.pone.0025584.g005
Susceptibility and Resistance to HCV Infection
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Cellular receptors and lipoproteins. Cellular receptors
and lipoproteins involved in HCV entry are differentially
expressed in comparisons between both resistant and susceptible
cells. Five genes – CLDN1, CD81, LDLR, ASGR1 and APOE –
that promote virus entry are differentially expressed in a
comparison between susceptible cells (figure 6). Of these five
genes, all except APOE are downregulated in the Huh-7.5.1 cell,
relative to Huh-7. APOE is transcriptionally upregulated in Huh-
7.5.1 relative to Huh-7 (a fold-change 1.84) and ASGR1 is
upregulated in Huh-7.5.1c2 relative to Huh-7.5.1 (a fold-change
1.57). Therefore, only APOE and ASGR1 are regulated in a
manner that fits with the observed susceptibility to infection and
neither undergo a substantial fold-change, thus, it does not seem
likely that enhanced viral entry is a cause of the relative
permissiveness to infection in Huh-7.5.1 and Huh-7.5.1c2 cells.
Ten factors that influence HCV entry are differentially
expressed in comparison between resistant cells and the Huh-
7.5.1 parent (DD81, ASGR1, ASGR2, CLDN1, CLDN6,
VLDLR, LDLR, APOC1, APOC2 and APOE). CD81, an
important coreceptor in HCV cell entry [13], is downregulated
in both R1.09 and R1.10 relative to Huh-7.5.1. CD81 expression
is significantly greater in R2.1 than Huh-7.5.1. However, eight of
the nine remaining differentially expressed entry factors, all except
for VLDLR, are downregulated in R2.1 relative to Huh-7.5.1,
including four by more than 32-fold (APOC2, APOE, ASGR1
and CLDN1). These results are consistent with the findings of
Zhong et al. who identify that low ectopic CD81 contributes to
the resistance of the original R1 (but not R2) cell, from which
R1.09 and R1.10 are descended. However, additional mecha-
nisms of resistance must exist, as transduction of R1 cells to
express CD81 did not fully restore the susceptibility to infection
observed in Huh-7.5.1 [20]. From our expression analysis it does
not appear that R1.09 and R1.10 cells lack other cell entry
factors. Therefore, the mechanism of resistance to infection,
additional to CD81-mediated entry in R1 derived subclones, is
unlikely to be due to viral entry. Zhong et al. attribute infection
resistance of R2 to processes other than CD81-mediated entry.
However, we identify that many entry factors aside from CD81
are downregulated in R2.1. These factors include CLDN1, a
component of tight junctions, the silencing of which prevents
HCV entry into Huh-7.5 cells [43]. CLDN1 is transcriptionally
downregualted in R2.1 compared to Huh-7.5.1, with a fold-
change of approximately 36-fold, indicating impeded viral entry
could contribute to R2.1 resistance to infection. However, like R1
and Huh-7.5 derived cells, evidence suggests that processes other
than viral entry affect the permissiveness of R2.1 to infection by
HCV; particularly as Zhong et al. show that HCV replicon
replication was defective in R2 cells and over five thousand genes
are differentially expressed following subcloning of R2.1 cell from
Huh-7.5.1. Indeed, MTTP and APOB are associated with HCV
particle formation and particle secretion [13]. Like the virus entry
factors previously mentioned, both MTP and APOB are
downregulated in R2.1 relative to Huh-7.5.1 by more than 32-
fold. Therefore, it appears that R2.1 cells may also lack the ability
to support aspects of the HCV replication cycle that take place
post-entry.
Proteins associated with the HCV replicase
complex. Host proteins from crude HCV replicase complexes
were identified by mass spectrometry. These host proteins
correspond to 236 host genes that we term host replication
factors (HRFs) (supplementary table S5). A total of 212 HRFs were
expressed among the cells that underwent microarray analysis and
145 of these are differentially expressed. This is significantly more
than would be expected by random chance (P=3.8610-5, Fisher’s
exact test). This result suggests that the ability of these cells to
support replication of viral RNA is unlikely to be consistent
between these cells. Interestingly, among these 145 host genes are
12 (APOA1, APOE, CALR, CANX, FTH1, GNB2, HSPA5,
OS9, PFN1, PPIB, SSR4, and TUBB2C) that encode a product
known to interact with one or more HCV proteins [10]. For
example, Chang et al. show that APOE is required for production
of infectious HCV, probably for virion assembly rather than viral
RNA replication [44] and CANX is involved in the folding of
HCV glycoproteins [45].
Also, among the 145 host genes are two HDFs, DDOST and
PPIA [5]. DDOST encodes a subunit (dolichyl-diphosphooligo-
saccharide-protein glycosyltransferase) of the oligosaccharyltrans-
ferase complex. DDOST is required during the late stages of HCV
replication, possibly to perform an essential glycosylation step on
HCV envelope proteins, E1 and E2 [5]. PPIA encodes a
cyclophilin A the protein target of anti-HCV drug alisporivir
[4]. Both DDOST and PPIA are downregulated in the R2.1
subclone compared to Huh-7.5.1 with fold change 2.16 and 1.82,
respectively. APOE encodes apolipoprotein E, a constituent of
lipoproteins. Surprisingly, the level of APOE gene expression in
R2.1 cells is lower than in Huh-7.5.1 by over 100-fold. Taken
together, these results suggest that the regulation of expression of
DDOST, PPIA and particularly APOE might be sufficiently
Figure 6. Hierarchical clustering plots showing the expression
levels of differentially expressed HCV-linked cellular receptors
and lipoproteins. Genes are represented by horizontal bands and
cells by columns. Bands are coloured blue if the gene is downregulated
and yellow if they are upregulated, relative to their expression in Huh-
7.5.1. Greater colour intensity relates to a greater fold change. Black
bands represent genes whose expression is a similar level to Huh-7.5.1.
(A) Comparison of gene expression levels between susceptible cells. All
genes shown are linked to HCV cell entry except for MTTP and APOB
that are associated with release of HCV from the cell. The majority of
these host factors that undergo a significant change in expression are
found at a higher level in Huh-7 than either of the Huh-7.5.1 derived
cells. (B) Comparison of gene expression levels between resistant cells
and Huh-7.5.1. R1.09 and R1.10 cells have have a lower level of
expression of CD81 than Huh-7.5.1. Though R2.1 cells have a relatively
high level of CD81 expression relative to Huh-7.5.1, other cell entry
factors are expressed at lower levels.
doi:10.1371/journal.pone.0025584.g006
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altered in R2.1 such that the cell are unable to form a competent
HCV replication complex.
Gene expression profiles highlight host factors and
biological functions that are linked to HCV infection
susceptibility
A significantly greater proportion of expressed genes appear on
multiple branches of the tree of cell subclones (figure 1B) than
would be expected by random chance (no Mann Whitney U test p-
value exceeded 0.001 in 1000 permutations). This result indicates
that the likelihood of undergoing a significant change in expression
following subcloning is not equal for each gene. This may be due
to a number of reasons including simple hyper- or hypo-variability
of certain genes, or, more interestingly, some genes being
differentially expressed multiple times during subcloning due to
an effect they have on HCV infection susceptibility, their change
in expression having been selected by subcloning.
To distinguish factors that may alter HCV susceptibility and to
identify specific biological functions and proteins that may
contribute to HCV infection susceptibility, we define a gene
expression profile score that accounts for significant change in
expression following independent subcloning events (see Materials
and Methods). A negative score represents an antiviral expression
pattern a positive score represents a proviral expression pattern. The
frequencies of attained scores are given in table 3 and a full list of
scores per gene is given in supplementary table S6. To demonstrate
the significance of our measure, we tested whether other gene sets
that are linked to HCV virus propagation have greater scores than
would be expected. We find that HCV-linked cellular receptors and
lipoproteins (including many factors involved with cell entry), genes
that encode proteins that interact with HCV proteins and HRFs
have a greater mean score than expected by random chance. The
test result was not significant for HDFs (see table 4). These results
indicate that our score is significant and is a useful measure for aiding
identification of host cell factors that affect susceptibility to HCV
infection. Furthermore, these results indicate that factors involved in
virus entry into the cell, replication and those that have a direct
association with proteins of HCV are likely to be important.
Though our score does penalise expression profiles that exhibit
both antiviral and proviral tendencies, we would still expect
biological functions that comprise genes that are hyper-variable in
their expression in the hepatoma cell culture system to have a
greater range of scores than biological functions whose genes tend
to be expressed at a constant level. Therefore, we devised a test to
ascertain whether the enriched functions that we highlight in
figure 5 are simply hyper-variable or are consistent with a profile
that corresponds to antiviral or proviral action (see Materials and
Methods for details of this test).
We find that two areas of function are linked to the observed
differences in susceptibility to HCV infection in more than one of
the six cell cultures: (i) secreted signal peptides and glycoproteins
(343 genes, figure 5B) and (ii) the acute and innate inflammatory
responses (71 genes, figure 5D) were significant (P=0.049 and
P=0.013 respectively). The innate immune response and
particularly interferon-stimulated pathways play an important
role in cellular defense against viral infection [46]. ‘‘Secreted signal
peptides and glycoproteins’’ is a description relevant to proteins
from a broad spectra of activities and there are several important
factors among these that are differentially expressed which directly
relate to HCV infection. These include TGF-b [47], low-density
lipoprotein receptors and their associated proteins that have
previously been discussed and TNF and serpin peptidase inhibitors
[13,48] (discussed in the next section).
We also define a set of ‘high-scorers’, genes with an absolute
score $3. There are 222 high-scorers, representing approxi-
mately the top 3% of differentially expressed genes. Genes that
scored .3 or ,3 are listed in table 5. Among high-scorers are
two HRFs, neutral cholesterol ester hydrolase 1 (NCEH1) and
visinin-like 1 (VSNL1). NCEH1 catalyses hydrolysis of intracel-
lular cholesterol ester, to produce free cholesterol. Free
cholesterol may then be re-esterified or efflux to an extracellular
cholesterol acceptor [49]. We identify NCEH1 as differentially
expressed comparisons corresponding to: subcloning of Huh-
7.5.1 from Huh-7, R1 from Huh-7.5.1, R1.09 from R1 and R2.1
from Huh-7.5.1. NCEH1 follows an antiviral expression profile
without deviation and scores -4. Visnins are calcium sensor
proteins that modulate multiple intracellular targets [50]. In
contrast to NCEH, VSNL1 has a unanimously proviral
expression profile of +3, as it is differentially expressed in three
comparisons corresponding to: subcloning of R1 from Huh-7.5.1,
R1.09 from R1, and R2.1 from Huh-7.5.1. Both of these genes
Table 3. The frequency of gene scores.
Score Frequency total Proportion
25 1 0.013%
24 11 0.15%
23 77 1.03%
22 592 7.89%
21 3039 40.50%
0 1042 13.89%
1 2054 27.38%
2 554 7.38%
3 113 1.51%
4 19 0.053%
5 1 0.013%
Here, we give the profile scores, the frequency of the score among 7503
differentially expressed genes and the corresponding proportion. A negative
score represents an expression profile that indicates a possible antiviral activity,
whereas a positive score indicates a possible proviral activity.
doi:10.1371/journal.pone.0025584.t003
Table 4. Mean profiles scores.
Gene set No. of genes Mean profile score Permuted p-value
Receptors 14 0.5 0.0070
HRFs 173 0.283 ,0.001
HDFs 230 20.0174 0.173
HCV interacting 465 0.0452 0.0030
Details of the profile scores of four gene sets that we predict may have a higher
score than would be expected by random chance. These gene sets are: HCV-
linked cellular receptors and lipoproteins, the majority of which facilitate virus
entry (but also particle formation and release, here labeled ‘‘receptors’’), host
factors that we isolate from vesicles that harbour the HCV replication complex
(HRFs), host factors that are required for HCV replication determined by siRNA
screen (HDFs) and HCV interacting proteins (HCV interacting). For each gene set
we show the mean profile score and the significance of the score enrichment,
determined by Mann Whitney U test permutation. For all gene sets other than
HDFs, the profile scores are on average greater than we would expect by
random chance, given a p-value cutoff of ,0.05.
doi:10.1371/journal.pone.0025584.t004
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are also differentially expressed in comparisons between infected
and uninfected cells; NCEH1 is upregulated in both infected
Huh-7.5.1 and Huh-7.5.1c2 cells compared to the uninfected
cells, whereas VSNL1 is downregulated in Huh-7.5.1c2 cells
following infection. Also, among high-scorers are three proviral
HDFs: PROX1, GCAT and ATP10D. In agreement with their
HDF status, these genes have unanimously proviral expression
profiles, each scoring +3. These high-scoring genes that appear in
multiple HCV-related data sources may have a significant role in
HCV infection.
Investigation of HCV protein neighbourhoods reveals
plausible mechanisms for change to infection
susceptibility
Investigation of the network neighbourhoods of HCV proteins
could identify plausible mechanisms for change in HCV infection
susceptibility (figure 7). In order to focus our search we only
investigated differentially expressed genes from high-scorers or
functional clustering networks corresponding to (i) secreted signal
peptides and glycoproteins and (ii) the acute inflammatory
response that we find to be significantly pro- and antiviral in
their expression. In addition, we only evaluated interactions
between these differentially expressed genes and HCV proteins,
HDFs, HRFs and HCV-linked cellular receptors and lipoproteins.
Control over STAT3 protein activation. Stat3 (signal
transducer and activator of transcription 3) is a transducer for a
variety of signals including response to cytokines and growth
factors. Upon activation by phosphorylation, Stat3 proteins
dimerize and are translocated to the nucleus where they act as
activators of transcription [51]. Stat3 is among the host cell
interactants of HCV NS3 and core proteins [10] and is activated
by core through a direct interaction, causing proliferation and
possibly promoting tumorigenesis [52]. In addition, Stat3 has been
shown in two independent siRNA screens to be essential for HCV
replication [5,28]. In contrast, other work has shown that Stat3
activation following interferon or IL6 treatment can prevent HCV
subgenomic replicon replication by inducing an antiviral response
[53]. Therefore, despite a clear importance, the effect of Stat3
signaling in HCV infected cells has yet to be fully understood.
In both the NS3 and CORE protein networks, we identify three
host proteins, encoded by genes IL6R (interleukin 6 receptor),
FGFR3 (fibroblast growth factor receptor 3) and IFNAR1
(interferon-a receptor 1), that act as activators of Stat3 activity.
IL6R is an activator of Stat3, in response to interleukin 6 [51]. IL6
is included in gene sets taken from functional clustering networks
(figures 5B and 0D) and has a profile score of +2. Specifically,
IL6R is upregulated in Huh-7.5.1 in comparison with Huh-7 (fold
change of 2.6) and downregulated in R2.1 in comparison with
Huh-7.5.1 (fold change of 6.1). This change in regulation,
combined with substantial fold changes purports a proviral action.
However, this is not consistent with the findings of Zhu et al. [53],
who show IL6 mediated signaling to be antiviral. FGFR3 is also
included in the gene set taken from the functional clustering
network (figure 5B), has a score of +2 and is downregulated in
R2.1 (fold change of 1.6) and R1.10 (projected fold change of 1.8)
following subcloning. Conversely, IFNAR1 has an negative score
of -2, as it is downregulated in both the Huh-7.5.1 and R2.1 cells
following subcloning, both with a fold change of 1.6. This activity
is consistent with the findings of Zhu et al. on the basis that the
IFN-induced antiviral activity can be mediated by this receptor.
Modulation of TNF-mediated signals and NF-kB
activation. HCV modulates the host innate immune response
using multiple strategies [54]. One of these strategies involves
regulation of TNF-induced NF-kB, a transcriptional regulator and
an important controller of inflammation and immune activation.
Several HCV proteins are known to regulate NF-kB including
NS5A, NS5B, core and F [55–58]. NF-kB activation is mediated
through engagement of the TNF receptor. Upon stimulation,
components of a signaling complex are recruited to the receptor.
Signaling complex formation requires adaptor proteins including
TRAF2 (TNF receptor associated factor family 2) [59]. NS5A
appears to negatively regulate TNF-a-mediated activation of NF-
kB through a direct interaction with TRAF2 [55]. However,
TRAF2 has been shown by siRNA screen to be necessary for
HCV replication [40], therefore it is unlikely that HCV infection
Table 5. Genes with top-scoring antiviral and proviral
expression profiles.
Gene name
Profile
score
infected vs.
uninfected
trophoblast glycoprotein 25 n n n
GalNAc-T7 24 + + +
sperm associated antigen 1 24 + + +
tubulin, alpha 1a 24 n + +
neutral cholesterol ester hydrolase 1 24 n + +
interleukin 17D 24 n n –
proline-serine-threonine phosphatase interacting
protein 2
24 n + n
discoidin domain receptor tyrosine kinase 1 24 n n +
lectin, galactoside-binding, soluble, 1 24 n n +
ependymin related protein 1 24 n n n
MHC class I polypeptide-related sequence B 24 n n n
TIMP metallopeptidase inhibitor 1 24 n n n
complement component 3 5 n – n
peptidoglycan recognition protein 2 4 – – –
potassium channel, subfamily T, member 2 4 – – –
coagulation factor XII (Hageman factor) 4 n – –
annexin A9 4 n – –
orosomucoid 2 4 n – –
complexin 1 4 n – –
hydroxysteroid (11-beta) dehydrogenase 2 4 n – –
transmembrane protein 86B 4 n – –
solute carrier family 7, member 10 4 n – –
haptoglobin 4 n – –
serpin peptidase inhibitor, clade C
(antithrombin), member 1
4 n – –
haptoglobin-related protein 4 n – –
left-right determination factor 1 4 n – n
reelin 4 + n n
argininosuccinate synthetase 1 4 n – n
ATP-binding cassette, sub-family B
(MDR/TAP), member 4
4 n n n
KIAA1462 4 n n n
orosomucoid 1 4 n n n
coagulation factor V (proaccelerin, labile factor) 4 n n n
Genes with a profile score of ,3 (antiviral profile) are listed above and .3
(proviral profile) are listed below the line. Also, given is the change in regulation
of the gene in Huh-7, Huh-7.5.1 and Huh-7.5.1c2 cells (in that order) from
uninfected versus infected comparisons, where ‘‘n’’ represents no significant
differential expression, ‘‘+’’ represents upregulation in the infected cell and ‘‘–’’
represents downregulation in the infected cell.
doi:10.1371/journal.pone.0025584.t005
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Figure 7. Protein interaction neighbourhoods of HCV proteins. HCV proteins are denoted by yellow nodes. Host proteins encoded by genes
from either the high-scorer set or from significant antiviral and proviral biological functions are denoted by orange or blue nodes, indicating proviral
or antiviral expression profiles, respectively. Other HCV interacting host proteins are denoted by grey nodes. Edges represent interactions between
these proteins.
doi:10.1371/journal.pone.0025584.g007
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simply requires suppression of TRAF2 activity. The sphingosine
kinase 1 (SPHK1) and its product, an anti-apoptotic lipid
mediator, sphingosine-1-phosphate, have recently been
confirmed as important factors in TRAF2-mediated NF-kB
activation [60]. The SPHK1 gene is expressed at a greater level
in Huh-7.5.1 cells when compared to Huh-7 and resistant cells and
is among the high-scorers with a score of +3, indicating that this
gene may play an important proviral role in HCV infection,
perhaps via a link to TRAF2 and an involvement in NF-kB
induction, prevention of apoptosis and regulation of the innate
immune response. We also identify two other genes among the
subset of differentially expressed genes that we investigated that
interact with TRAF2: CHMP2B (chromatin modifying protein
2B) and putative gene C5orf55. Both C5orf55 and CHMP2B have
negative scores of 22 and 23, respectively, indicating a possible
antiviral link. This provides additional evidence that TRAF2-
related processes may have an effect during HCV infection.
Phospholipid scramblase 1 as an enhancer of interferon
signaling. Interferons are important regulators of the innate
immune response to viral infection [46]. Indeed, interferon-a is
used as a treatment to reduce viral load in HCV infected patients
[2]. PLSCR1 (phospholipid scramblase 1) is an interferon-
stimulated gene that contributes to the interferon-mediated
antiviral response. Though the underlying mechanism for
antiviral activity of PLSCR1 remains to be fully understood,
evidence indicates that this action is dually mediated at the cell
membrane, where PLSCR1 can alter the distribution of
phospholipids and in the nucleus, where this protein binds to
DNA, possibly to potentiate transcription [61]. PLSCR1 appears
in the gene set taken from the functional clustering network
(figure 5D) and has a score of 22, as a result of being upregulated
in all resistant cells (with fold changes of between 1.6 and 2.2),
relative to Huh-7.5.1. In addition, PLSCR1 interacts with HCV
core, indicating a mechanism through which HCV may act to
control PLSCR1 signaling [10]. Therefore, PLSCR1 is a
candidate for increased resistance to infection of R1.09, R1.10
and R2.1 cells.
Cholesterol efflux. A link between cholesterol efflux and
HCV infection has been made previously. The scavenger receptor
SR-BI mediates cellular uptake of cholesterol and the flux of
cholesterol between HDL and the cell [62]. SR-BI is also an
important HCV virus entry factor, possibly promoting viral entry
through regulation of plasma membrane organisation, being a
provider of cholesterol and interaction with other entry factors
[13]. Virion-associated cholesterol is also a requirement of HCV
infectivity [63]. We have previously mentioned the antiviral
expression profile of NCEH1 and it’s inclusion among high-scorers
and HRFs. Another host protein with a related role is ATP-
binding cassette protein (ABCA1). This protein is a cholesterol
efflux pump for removal of cellular lipids [64]. ABCA1 is among
the gene set taken from the functional clustering network
(figure 5B) and unlike NCEH1 it has a proviral profile score of
+2. The ABCA1 encoded protein effluxes cholesterol to
apolipoprotein A-I, a major constituent of HDL and these two
proteins interact directly. Apolipoprotein A-I is present among
HRFs and also interacts directly with HCV NS5A, probably as
part of HCV-associated lipid metabolism dysregulation [65]. This
evidence suggests that enzymes with the ability to alter the balance
of cholesterol efflux may also impact HCV infection. Therefore,
ABCA1 and NCEH1 may have an effect on susceptibility to HCV
infection in hepatoma cells.
Serpins as mediators of HCV NS3 protein activity. HCV
NS3 protein is a serine protease that contains a helicase domain
and a serine protease domain. NS3 is responsible for cleavage of
viral polyproteins and disruption of host innate immune response
[66]. NS3 protease action is inhibited by serpin C1 through a
direct physical interaction [48] and serpin-mediated inhibition of
NS3 has been proposed as a possible anti-HCV therapy [48,67].
However, we find that SERPINC1, the gene that encodes serpin
C1 and a second serpin encoding gene SERPINA6 are among the
high scorers with proviral expression profiles that score +4 and +3
respectively and these instances of differential expression also
include substantial fold-changes. Serpin C1 has also been found to
interact with the HCV F protein [68], NS3 also interacts with
other serpins G1 and F2, and serpins C1 and G1 are both found in
the NS4B PPI network neighbourhood (figure 7). The latter serpin
genes all have proviral expression patterns. Furthermore, we also
identified that serpins encoded by genes SERPINH1 and
SERPINA1 are part of the HCV replication complex. These
results raise the question of whether serpins play an additional
proviral role in mediation of NS3 (and possibly F and NS4B)
protein activity HCV life cycle, possibly as part of the HCV
replication complex.
Conclusion
In this study we performed multiple genome scale expression
studies of Huh-7 derived hepatoma cells with the aim of
identifying genes and biological functions that have a significant
role in HCV infection. This permitted a detailed account of
changes to gene expression caused by HCV infection, determined
key differences between cells commonly used for HCVcc and
implicated novel host factors in determining cellular permissive-
ness to infection.
Firstly, by comparing uninfected and infected hepatoma cells we
identified a set of host cellular functions that are regulated during
HCV infection including proteins associated with microtubule
organisation, ubl conjugation, zinc-finger domain-containing
transcription factors and proteins with helicase activity (supple-
mentary table S2). Though proteins involved in microtubule
organisation, ubiquitination and DEAD-box helicases have
previously been identified as differentially expressed following
HCV infection of hepatoma cells in vitro [12], the sensitivity of our
study has highlighted the breadth of regulation of genes with these
functions. In addition, we identify transcriptional upregulation of
ubiquitin specific peptidases as a particular mark of HCV infection
in Huh-7 derived cells. Furthermore, our results indicate that
transcriptional upregulation of anti-apoptotic and proliferation
stimulating factors may be a cause of increased permissiveness to
HCV infection in Huh-7.5.1c2 cells.
Secondly, we examined the expression profiles of six hepatoma
cells that have been subcloned from Huh-7, including three cell
types that are resistant to HCV infection and genes differentially
expressed between subcloned cells and their parent cells were
identified. We were able to confirm that cells derived from the R1
subclone have significantly reduced levels of CD81 owing to a
mechanism that acts at the level of gene expression. Additionally,
we identified 236 host factors that are associated with the HCV
replication complex in the membranous web of infected cells
(HRFs, supplementary table S5). This is the largest set of HRFs
that has been identified to date. From HRFs we implicate change
in expression of APOE, DDOST and PPIA in the resistance to
infection of the R2.1 cell. We also identify a subset of HRFs that
interact with HCV proteins including APOE, CALN that are
known to be involved in production of HCV [44,45]. We scored
genes according to their expression profile and used these scores to
identify antiviral and proviral candidate genes. Table 5 lists the top
scoring genes that include both novel candidate host factors and
factors linked to HCV replication, such as tubulin-a [26] and two
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HRFs, NCEH1 and VSNL1; NCEH1 is a potentially antiviral
factor and VSNL1 is a potentially proviral factor.
Our analysis of HCV infected cells also highlighted the ability of
HCV to attenuate interferon upregulation, even in the Huh-7 cell
that, unlike Huh-7.5 derived cells, is not reported to have a
defective RIG-I signaling pathway. However, when we performed
a meta-analysis of gene expression in the six uninfected Huh-7
derived cells, five of which are subcloned from Huh-7.5, we
identify that the acute and innate inflammatory responses, as well
secreted signal peptides and glycoproteins, are likely to be linked to
differences in susceptibility to infection between these subclones.
Furthermore, we can predict that these mechanisms of suscepti-
bility or resistance to infection are independent of RIG-I signaling.
Following these observations network neighbourhoods of HCV
proteins were explored and hypotheses for changes to susceptibility
to infection were postulated that involve novel HCV-related
factors including ABCA1, SPHK1 and CHMP2B, in addition to
supporting previously implicated factors such as PLSCR1 [10] and
STAT3 [10,52].
Interestingly, we find that secreted proteins (particularly
glycoproteins) are linked to HCV infection. Genes with this
annotation are over-represented among differentially expressed
genes from multiple parent-child subclone comparisons and we
identify these as having more significant proviral and antiviral
expression profiles than would be expected than by random
chance. Among these secreted proteins are factors involved in
coagulation, such as complement components, serpins and
coagulation factors and these factors have largely proviral
expression profiles (see table 5 for some examples). Indeed,
members of complement and coagulation pathways have previ-
ously been identified as potentially important cellular cofactors of
NS4B through yeast two-hybrid and functional network analysis
[69]. Also, among HRFs are factors that have a role in folding and
secretion of coagulation factors, such as CALR and CANX [70],
and CANX is also involved in production of HCV glycoproteins
[45]. Hence, changes in HCV infection susceptibility could relate
to the ability of the cells to produce viral glycoproteins. For
example, HSPA5 encodes a heat-shock protein that is involved in
protein folding and assembly in the endoplasmic reticulum [71].
HSPA5 is downregulated in all HCV resistant cell types compared
to Huh-7.5.1 with approximate fold-changes between 1.5 and 2,
though with highly significant probability (fdr ,1610-7 in each
case). Other host factors with chaperone and protein folding
activity that achieve high profile scores and appear in HCV
protein network neighbourhoods include heat-shock proteins
DNAJC1 and HSP90B1 [72,73]. Another heat-shock protein,
Hsp90, has been shown previously to form a complex that includes
HCV NS5A and has an important role in HCV RNA replication
[74]. Investigation of the ability of these chaperones to influence
virus protein production will potentially identify additional
mechanisms important to HCV infection.
Overall, our study builds upon current knowledge of infection
and our results may contribute to the development of new
antiviral treatments to counter the global HCV problem,
particularly where we identify potentially proviral proteins that
could act as drug targets. Further study, such as genomic
sequencing of Huh-7 derived cells would provide greater insight
in to the extent that these cells mutate in order to effect the
extensive differences in gene expression that we observe following
subcloning. Changes to susceptibility to infection could then be
attributed to gene-specific mutations, in the same way that Huh-
7.5 susceptibility has been linked to mutation of RIG-I. Genome
sequencing may also highlight other previously undetected
mutations in Huh-7.5.1 as well as other Huh-7 derived cells to
further our understanding of HCVcc systems and their suitability
for modeling infection.
Materials and Methods
HCV-resistant cells R1.09, R1.10 and R2.1
R1 and R2 cells were obtained from stocks held at the The
Scripps Research Institute, La Jolla, California, from a previous
study [20]. Cryopreserved cells were thawed and put in culture.
Initially, both cells displayed very limited viability after two
independent thawing attempts of the original cryopreserved stock.
Nevertheless, we were able to rescue both cell lines by slowly
expanding the surviving colonies, subsequently labelled R1.1 and
R2.1. To verify the resistance of these cell lines to HCV Con1
(genotype 1b) subgenomic (SG)-replicon replication, R1.1, R2.1
and the parental Huh-7.5.1 cells were transfected with the
corresponding replicon RNA encoding a neomycin resistance
gene and the formation of G418 resistant cell clones was
monitored. R1.1 and R2.1 cells are partially resistant to HCV
replication (supplementary figure S2A). However, a higher
percentage of cell clones in the R1.1 and R2.1 cell lines seem to
support HCV replication than was previously observed in R1 and
R2 cells before cryopreservation [20]. To verify that this result was
reproducible for other replicon RNA preparations, we repeated
the transfection experiment using Con1 full-length replicon RNA
to select HCV replication resistant cell clones within the R1.1 and
R2.1 cell populations (supplementary figure S2B). R1.1 and R2.1
cells were subcloned by limiting dilution on feeder cells. Individual
subclones were tested for resistance to subgenomic Con1 replicon
replication and subclones R1.09, R1.10 and original R2.1 cells
were selected for further analysis (supplementary figure S2C).
R1.09, R1.10, R2.1 and Huh-7.5.1 were harvested for microarray
analysis.
HCV susceptible cells, Huh-7, Huh-7.5.1 and Huh-7.5.1c2
Three Huh-7 derived cell cultures that can support HCV
infection [75,76] were used in this study – Huh-7, Huh-7.5.1 and
Huh-7.5.1c2. Cells were obtained from stocks held at the The
Scripps Research Institute, La Jolla, California. All cells have been
used in previous studies (Huh-7 [76], Huh-7.5.1 [16] and Huh-
7.5.1c2 [19]).
The HCV susceptible cell types, Huh-7, Huh-7.5.1 and Huh-
7.5.1c2, were infected with wild type JFH-1 (genotype 2a) virus at
an moi = 0.05. Infected cells were harvested for microarray
analysis when virtually 100% of the cells were infected as
determined by staining of cells for viral E2 protein at 3 (Huh-
7.5.1c2), 4 (Huh-7.5.1) and 7 (Huh-7) days post inoculation
(supplementary figure S2D). Uninfected controls were harvested at
the same time point as infected cells. The infectivity of supernatant
produced from infected cells was measured at 2, 4 and 8 days post
infection (supplementary figure S2E). These results show that
Huh-7 has the lowest susceptibility and Huh-7.5.1c2 the greatest
susceptibility to HCV infection. In addition, uninfected Huh-7,
Huh-7.5.1 and Huh-7.5.1c2 cells were harvested at 20 hours post
infection in order to perform direct comparisons of their gene
expression profiles by microarray analysis.
Preparation of microarrays
Cell cultures were centrifuged at 1000 rpm for 5 minutes and
the cell pellet was resuspended in 350 ml lysis buffer (Qiagen).
Each lysate was homogenised with a Qiashredder column
(Qiagen) and the RNA was extracted using the RNeasy Mini
Kit following the manufacturers instructions. On-column DNA
digestion was carried out by means of the RNase-Free DNase Set
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(Qiagen) and the integrity of the RNA was confirmed via Agilent
(RIN of 9.7–10). 100 ng of RNA from each sample was used to
prepare cDNA with the Affymetrix GeneChip 3 IVT Express Kit
and hybridised to Affymetrix U133 Plus 2 microarrays following
the manufacturer’s instructions.
The washing and staining procedure was performed in the
Affymetrix Fluidics Station 450. The probe array was exposed to
10 washes in 66SSPE-T at 250 C followed by 4 washes in
0.56SSPE-T at 500 C. The biotinylated cRNA was stained with a
streptavidin-phycoerythrin conjugate, final concentration 2 mg/
ml (Molecular Probes, Eugene, OR) in 66SSPE-T for 30 min at
250 C followed by 10 washes in 66SSPE-T at 250 C An antibody
amplification step followed using normal goat IgG as blocking
reagent, final concentration 0.1 mg/ml (Sigma) and biotinylated
anti-streptavidin antibody (goat), final concentration 3 mg/ml
(Vector Laboratories). This was followed by a staining step with a
streptavidin-phycoerythrin conjugate, final concentration 2 mg/
ml (Molecular Probes, Eugene, OR) in 66SSPE-T for 30 min at
250 C and 10 washes in 66SSPE-T at 250 C. The probe arrays
were scanned at 560 nm using a confocal laser-scanning
microscope (Affymetrix Scanner 3000 7G). CEL files were
generated and used for further analysis. All microarray procedures
were done at AROS, Denmark.
Computational analysis of microarray probe set intensity
data
All analysis of microarray intensity data was carried out using R
statistical software [77] including Bioconductor [78]. GeneChipH
probe sets definitions were assigned using Entrez gene version 12.1
of a custom chip description file (CDF) from Psychiatry/MBNI
Microarray Lab [79–82]. This CDF included 17726 probe sets
that correspond to an NCBI gene.
Initial quality checks of each chip were carried out using
Bioconductor core tools and package affyQCReport [83]. Quality
checks and visual inspection of array intensities showed that the
quality of the array data was acceptable. Robust Multichip
Average (RMA) expression values [82,84,85] were computed using
the Bioconductor affy package. Genes that were called ‘‘not
present’’ on all 39 GeneChip array data sets using Microarray
Suite version 5.0 (MAS5) presence calls were removed [86],
leaving a total of 13760 genes (supplementary table S7). This set
was used throughout as a background for statistical tests and will
be referred to as the microarray gene set.
Exploration of RMA expression values across all microarray
chips was performed by PCA using singular value decomposition
(SVD). PCA was carried out using the Bioconductor package
pcaMethods [87] and PCA results were plotted using the R
package scatterplot3d. PCA results (supplementary figure S3) show
that biological replicates cluster together. The greatest variation is
seen between replicates from experiment 1 that have been in
culture for a longer time period with no JFH-1 infection. However,
replicates that have been infected with JFH-1 cluster very closely,
indicating a clear gene expression response to infection. Replicates
from experiment 2 are all very tightly clustered and Huh-7.5.1
replicates from experiment 2 generally cluster with other
uninfected Huh-7.5.1 derived cells. The PCA analysis results
showed no major outliers or unexpected results and the array
quality was shown to be acceptable. Therefore, the microarray
data appeared sufficiently reliable to conduct analysis to identify
differentially expressed genes.
Probability, false discovery rate (FDR) [88] and fold-change
values for differential expression of genes between cells, using three
biological replicates from each, were calculated in a pairwise
manner using the limma method [89]. Genes were defined to be
significantly differentially expressed if they achieved an FDR of
,0.01 and a minimum fold-change of 1.5. Hierarchical clustering
of genes across cells was performed in R using Pearson’s r
correlation (genes) and Spearman’s rank correlation (cells) and
results were visualised using the gplots package [90].
The design of our experiment permitted HCV infected cells Huh-
7, Huh-7.5.1 and Huh-7.5.1c2 to be compared to uninfected
controls harvested after 20 hours in culture and also uninfected
controls harvested at the same time point as infected cells. We define
those genes that are differentially expressed due to infection as genes
that are significantly differentially expressed in the same direction
(up- or downregulated) over both comparisons, as this will filter out
genes whose expression fluctuates due to additional time spent in
culture. We take the p-value, fdr and fold-change values from the
comparison with the most conservative comparison.
MIAME compliant raw and processed gene expression data is
available for download as a GEOarchive [91], accession number
GSE29889.
Purification of crude replicase complexes (CRCs) for
proteomic analysis by mass spectrometry
CRC preparations were produced using a protocol described by
Quinkert et al. [92]. Protein samples from purified, proteinase K-
treated CRCs were fractionated by one-dimensional SDS-PAGE
and the gel was segmented according to molecular weight.
Proteins contained in gel segments were digested with proteinase
(trypsin/chymoptrypsin) prior to analysis by liquid chromato-
graph-mass spectrometry (WFZ Fungene, Greifswald). Using this
method, 236 host-encoded proteins were identified as components
of HCV replication complexes.
Collection of external gene sets
Four sets of genes that relate to replication of HCV were
collected from external sources:
(i) Genes that encode products that interact with proteins of
HCV were retrieved from two studies [10,69]. We
identified 465 such genes that correspond to an NCBI
protein.
(ii) A non-redundant list of genes that have been identified by
siRNA screen to play a significant role in HCV replication
were obtained from five separate studies [5,28,40–42].
This list contains 399 genes, including 363 that were shown
to be necessary for propagation of HCV (proviral) in one
or more study, and 37 that have been shown to be
detrimental to HCV propogation (antiviral) from the study
by Brass et al.. Brass et al. identify 203 genes (193 proviral,
10 antiviral) that act during an early stage of infection and
59 genes (44 proviral, 15 antiviral) that act during a late
stage in the viral life cycle.
(iii) Human host genes that are differentially regulated due to
chronic infection by HCV were mapped from an in vivo
study comparing chronically infected chimpanzees to
uninfected controls [93].
(iv) 27 Cellular receptors and lipoproteins that are thought to
have a role, either via positive or negative, in regulating
HCV virion cell entry or particle release were manually
curated from a recent review article [13]. These genes, by
gene symbol are CD81, CD209, CLEC4M, CLDN1,
CLDN6, CLDN9, SCARB1, LDLR, VLDLR, ASGR1,
ASGR2, OCLN, APOC1, APOC2, APOE, APOB,
MTTP, ISGF8, SAAL1, SAA4, EIF2A, EIF2AK2,
IFNA2, IFNA5, IFNA8, IFNA16 and APOC3.
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Assignment of differentially expressed genes to a cell
tree and calculation of expression profile scores
A tree showing the lineage of relevant cells is shown in figure 1.
Changes in gene expression were assigned to branches of this tree
directly from comparison of the ancestor and descendent cell,
except for those branches linking R1 to other cells, which were
imputed using a simple parsimony method. Genes identified as
differentially expressed in comparisons Huh-7.5.1 versus R1.09,
Huh-7.5.1 versus R1.10 or R1.09 versus R1.10 were assigned to:
(i) The branch linking Huh-7.5.1 and R1 if the gene is called
differentially expressed and undergoes the same direction of
regulation (up/down) in both comparisons involving Huh-7.5.1.
(ii) The branch linking R1 to a descendent cell if the gene is only
called differentially expressed with a given direction in just one of
the two comparisons involving Huh-7.5.1. (iii) The branch linking
R1 to a descendent cell if the gene is called differentially expressed
in the comparison between R1.09 and R1.10; in this case, the
descendent and direction of regulation is chosen from the
comparison involving Huh-7.5.1 and a descendent where the
largest fold change is observed.
To test whether genes appear more regularly on multiple
branches of this tree than would be expected by random chance a
permutation test was used. In a single permutation of this test we
assign genes to branches of a model tree by randomly selecting
them from the microarray gene set, selecting the same number of
genes per branch as observed in the real tree. We then derive the
frequency distribution for genes appearing in branches of the
model tree. The frequency distribution for the model data is
compared to the frequency distribution from the real data by
Mann-Whitney U test to generate a p-value, testing the hypothesis
that the real data values will be greater than that of the model
data.
Using the tree and associated sets of differentially expressed
genes, expression profiles consisting of an integer score per gene
were derived. Where a gene changes regulation on a branch
linking a more HCV susceptible parent cell to a more HCV
resistant descendant cell, the profile scores -1 if the gene is
upregulated (antiviral) and +1 if the gene is downregulated
(proviral). Where a gene changes regulation on a branch linking a
more resistant parent to a more susceptible descendant, the profile
scores -1 if the gene is upregulated and +1 if the gene is
downregulated. The overall gene profile score is calculated as the
sum of these values over all tree branches. Genes that are present
in the microarray gene set but not among the differentially
expressed genes on this tree were assigned a score of zero.
A permutation test was used to test the hypothesis that a given
gene set comprises genes with greater expression profile scores
than would be expected by random chance. A distribution of
scores from a set of subject genes were compared against the
distribution of scores from all remaining genes from the
microarray universe in a one-tailed Mann Whitney U test to
identify whether the subject set has significantly greater scores than
expected. The test statistic (U) for this test was recorded. We then
repeated this test using a subject gene set of randomly selected
genes, recording U for every permutation. 1000 permutations
were carried out. The p-value was determined to be the
proportion of times a more significant U value was generated by
random permutation than for a real subject gene set.
A permutation test was used to test if genes from a given set have
greater absolute expression profile scores given the number of times
that the genes are differentially expressed, than would be expected
by random chance. Using this measure we can ascertain whether
the subject genes have a genuine tendency to be proviral or
antiviral, or if they are simply hyper-variable in their gene
expression. For each gene in the set we calculated a normalised
score (S-norm), being the expression profile score divided by
differential expression count. If the gene set has a significant
tendency for the genes to be proviral or antiviral rather than hyper-
variable, we would expect the S -norm to be greater than those for
randomly selected genes. Hence, we test whether the genes of the
subject set have a greater mean S -norm than a gene set of the same
size, selected at random from the microarray gene universe. When
randomly sampling genes, we maintain the distribution of
differential expression counts observed in the subject gene set using
rejection sampling. The p-value for the test was determined to be
the total number of times that the random set has a greater mean
average S -norm than the subject set, divided by the number of
permutations. 1000 permutations were performed.
Analysis of the biological function of genes
Gene sets were subjected to functional enrichment using the
Database for Annotation, Visualisation and Integrated Discovery
(DAVID) version 6.7 functional annotation clustering and
functional annotation chart tools [94,95]. In both cases a custom
background population consisting of the microarray gene set was
used. All remaining DAVID 6.7 tools settings were left as the
default. The set of differentially expressed genes from the
comparison between Huh-7.5.1 and R2 cells was limited to
3000 by selecting the set with lowest p-values for differential
expression, as this corresponds to the maximum gene set size that
can be analysed using DAVID. Annotation clusters were deemed
to be significant if the enrichment score was .2, this corresponds
to a geometric mean from all term enrichment p-values of 0.01.
Functional clustering networks were produced using results from
DAVID functional annotation clustering. Significant annotation
clusters were represented as nodes, where the node diameter is
proportional to the enrichment score. Edges signifying shared
annotation were created between nodes where the annotation clusters
being represented share at least one quarter of annotating terms,
where the edge diameter is proportional to the fraction of shared
annotation terms. Networks were visualised using Cytoscape [96].
Construction of HCV protein network neighbourhoods
Human protein interaction data was retrieved from multiple
sources compiled by the National Centre for Biotechnology
Information (NCBI) and available as a download (ftp://anonymous
@ftp.ncbi.nlm.nih.gov/gene/GeneRIF/interactions.gz). NCBI in-
teractions data was downloaded on 10th August 2010. Physical
protein-protein binding interactions were taken per gene, not
including homo-dimer interactions (i.e., self edges in the network).
All retrieved interactions, were used to compile a global interaction
network where each interaction is treated uniformly, consisting of
48467 interactions between 10360 genes. HCV-human PPI data was
retrieved from two HCV-human interaction studies [10,69], on a per
HCV protein-human gene basis and consisted of 533 interactions
including 465 human genes and 11 HCV proteins. HCV protein
network neighbourhoods were constructed that included specific
differentially expressed genes and data from additional data sets. First
a node corresponding to a HCV protein was created, next additional
nodes corresponding to HCV-interacting host factors were added
and finally we added nodes corresponding to differentially expressed
genes that share an interaction with factors already present in the
network. Finally, nodes that correspond to those non-differentially
expressed host genes that do not share an interaction with a
differentially expressed gene were pruned. The result is a network
where the maximum path length from the HCV protein is two and
the maximum path length for a non-differentially expressed host
gene is one. Networks were visualised using Cytoscape [96].
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Supporting Information
Figure S1 Functional annotation cluster networks from differ-
entially expressed genes and other HCV-related data sources.
These networks highlight areas of shared enriched function
between gene sets that we identify as differentially expressed
between hepatoma cells and also gene sets that relate to HCV
infection. Nodes represent annotation clusters from the data
source denoted by the node colour. Edges represent shared
annotation terms between clusters. Only nodes that share at least
1/4 of annotating terms are connected by an edge. Node diameter
is proportional to the level of enrichment of the biological function
in the gene set. Edge width is proportional to the proportion of
annotating terms shared between two clusters.
(PDF)
Figure S2 (A) Huh-7.5.1, R1.1 and R2.1 G418 resistant colonies
transfected with HCV genotype 1b (Con1) subgenomic replicon
encoding a neomycin resistance gene. (B) Huh-7.5.1, R1.1 and
R2.1 G418 resistant colonies transfected with Con1 full-length
replicon RNA encoding a neomycin resistance gene. (C) Huh-
7.5.1, R1.09 and R1.10 G418 resistant colonies transfected with
HCV genotype 1b (Con1) subgenomic replicon encoding a
neomycin resistance gene. (D) Staining of HCV infected cells for
viral E2 protein at 3 (Huh-7.5.1c2), 4 (Huh-7.5.1) and 7 (Huh-7)
days post inoculation.(E) Infectivity of supernatant produced from
infected cells at 2, 4 and 8 days post infection.
(PDF)
Figure S3 PCA analysis was carried out on RMA expression
values of each array. Principal components 1, 2 and are plotted for
each array.
(PDF)
Table S1 Results of differential expression analysis including
Entrez gene ID, cell comparison in which the gene is differentially
expressed, log fold change, p-value and corrected p-value.
(TXT)
Table S2 Output from DAVID 6.7 functional annotation
clustering on subsets of genes that are differentially expressed
following HCV infection. Only annotation clusters that have an
enrichment score .2 are shown. Sheets A–G correspond to the
gene sets that are illustrated in Figure 3 in the main text.
(XLS)
Table S3 Differentially expressed genes assigned to branches of
the tree of cells. Shown are the Entrez gene IDs, the tree branch to
which the differentially expressed gene is ascribed and the cells in
which the gene is up- and downregulated.
(TXT)
Table S4 Output from DAVID 6.7 functional annotation
clustering. The first six sheets show results for gene sets that are
differentially expressed on a specific branch of the tree of cells. The
following three sheets show results from genes that are differen-
tially expressed in HCV susceptible cells following infection. The
remaining six sheets show results for other HCV-related data sets:
HCV-linked cell receptors and lipoproteins, HRFs, HDFs, two sets
of HCV-protein interacting factors (from studies [10] and [69],
respectively) and genes differentially expressed during chronic
HCV infection [93]. Only annotation clusters that have an
enrichment score .2 are shown. Each sheet shows results from a
different branch and sheets are named accordingly.
(XLS)
Table S5 List of HCV replication factors (HRFs). Shown is the
Enrez gene ID, gene name and protein accession.
(XLS)
Table S6 Expression profile scores for genes that were
differentially expressed (DE) and assigned to a tree branch
(supplementary table S5.6). Shown are the Entrez gene ID,
number of times the gene is found to be differentially expressed,
the overall pattern of gene regulation, the score (s) and normalised
score (s-norm).
(TXT)
Table S7 The microarray gene set following removal of genes
that are not expressed in any cell type (see Materials and Methods
for details). Shown are the array annotation ID, Entrex gene ID,
gene symbol and gene name.
(TXT)
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